Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

HC Wainwright & Co. Maintains Buy on Eyegate Pharmaceuticals, Lowers Price Target to $11

Author: Benzinga Newsdesk | August 16, 2021 10:20am
HC Wainwright & Co. analyst Yi Chen maintains Eyegate Pharmaceuticals (NASDAQ:EYEG) with a Buy and lowers the price target from $14 to $11.

Posted In: EYEG